Scilight Press

Author Information

Received: 15 Aug 2025 | Revised: 07 Feb 2026 | Accepted: 09 Feb 2026 | Published: 03 Mar 2026

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

food-derived bioactive peptides | neurodegenerative disease | renin angiotensin system | neuroinflammation | blood-brain barrier

References 

• 1.

  Adampourezare, M.; Hasanzadeh, M.; Nikzad, B. Recent progress and challenges in the application of molecularly imprinted polymers for early-stage screening of neurodegenerative diseases-related protein biomarkers. Microchem. J. 2023, 192, 108931.

• 2.

  Calderon-Garciduenas, L. Common Fatal Neurodegenerative Diseases Revisited: Beyond Age, Comorbidities, and Devastating Terminal Neuropathology There Is Hope with Prevention. Front. Neurol. 2022, 13, 901447.

• 3.

  Gadhave, D.G.; Sugandhi, V.V.; Jha, S.K.; et al. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res. Rev. 2024, 99, 102357.

• 4.

  Imam, F.; Saloner, R.; Vogel, J.W.; et al. The Global Neurodegeneration Proteomics Consortium: Biomarker and drug target discovery for common neurodegenerative diseases and aging. Nat. Med. 2025, 31, 2556–2566.

• 5.

  Alzheimer’s Association. 2023 Alzheimer’s Disease Facts and Figures; Alzheimer’s Association: Chicago, IL, USA, 2023; pp. 1598–1695.

• 6.

  Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures; Alzheimer’s Association: Chicago, IL, USA, 2024; pp. 3708–3821.

• 7.

  Jia, L.; Du, Y.; Chu, L.; et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: A cross-sectional study. Lancet Public. Health 2020, 5, e661–e671.

• 8.

  Alzheimer Europe. Dementia in Europe Yearbook 2019: Estimating the Prevalence of Dementia in Europe; Alzheimer Europe: Luxembourg, 2020; p. 16.

• 9.

  Su, D.; Cui, Y.; He, C.; et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: Modelling study of Global Burden of Disease Study 2021. BMJ 2025, 388, e080952.

• 10.

  Lei, J.; Gillespie, K. Projected Global Burden of Brain Disorders Through 2050 (P7-15.001). Neurology 2024, 102, 3234.

• 11.

  Nandi, A.; Counts, N.; Chen, S.; et al. Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: A value of statistical life approach. EClinicalMedicine 2022, 51, 101580.

• 12.

  Liu, T.; Li, J.; Sun, L.; et al. The role of ACE2 in RAS axis on microglia activation in Parkinson’s disease. Neuroscience 2024, 553, 128–144.

• 13.

  Ramalingam, M.; Jang, S.; Jeong, H.S. Therapeutic Effects of Conditioned Medium of Neural Differentiated Human Bone Marrow-Derived Stem Cells on Rotenone-Induced Alpha-Synuclein Aggregation and Apoptosis. Stem Cells Int. 2021, 2021, 6658271. 

• 14.

  Dolgacheva, L.P.; Zinchenko, V.P.; Goncharov, N.V. Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease. Int. J. Mol. Sci. 2022, 23, 13043.

• 15.

  Zhang, J.; Zhang, Y.; Wang, J.; et al. Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct. Target. Ther. 2024, 9, 211.

• 16.

  Dzidic-Krivic, A.; Fajkic, A.; Farhat, E.K.; et al. Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments. Mol. Neurobiol. 2025, 62, 14344–14366.

• 17.

  Luther, J.M.; Brown, N.J. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol. Sci. 2011, 32, 734–739.

• 18.

  Sarkar, S.; Jayachandra, K.; Vishwanath, B.S. ACE 2/Ang (1–7)/Mas, Non-conventional RAS Axis: Endogenous Contributor of Cardio, and Reno-protective Responses. J. Cell. Signal. 2024, 5, 149–161.

• 19.

  Loera-Valencia, R.; Eroli, F.; Garcia-Ptacek, S.; et al. Brain Renin-Angiotensin System as Novel and Potential Therapeutic Target for Alzheimer’s Disease. Int. J. Mol. Sci. 2021, 22, 10139.

• 20.

  Alenina, N.; Bader, M. ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models. Neurochem. Res. 2019, 44, 1323–1329.

• 21.

  Rocha, N.P.; Simoes, E.S.A.C.; Teixeira, A.L. Editorial: The Role of the Renin-Angiotensin System in the Central Nervous System. Front. Neurosci. 2021, 15, 733084.

• 22.

  Miners, J.S.; Ashby, E.; Van Helmond, Z.; et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 2008, 34, 181–193.

• 23.

  Jeon, S.; Salvo, M.A.; Alia, A.O.; et al. Neuronal ACE1 knockout disrupts the hippocampal renin angiotensin system leading to memory impairment and vascular loss in normal aging. Neurobiol. Dis. 2024, 202, 106729.

• 24.

  Tayler, H.M.; Skrobot, O.A.; Baron, D.H.; et al. Dysregulation of the renin-angiotensin system in vascular dementia. Brain Pathol. 2024, 34, e13251.

• 25.

  Kobiec, T.; Otero-Losada, M.; Chevalier, G.; et al. The Renin-Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene. Front. Synaptic Neurosci. 2021, 13, 638519.

• 26.

  Sica, D.A. Angiotensin-Converting Enzyme Inhibitors’ Side Effects—Physiologic and Non-Physiologic Considerations. J. Clin. Hypertens. 2005, 7, 17–23.

• 27.

  Novotny, M.; Klimova, B.; Valis, M. Microbiome and Cognitive Impairment: Can Any Diets Influence Learning Processes in a Positive Way? Front. Aging Neurosci. 2019, 11, 170.

• 28.

  Lu, Z.; Sun, N.; Dong, L.; et al. Production of Bioactive Peptides from Sea Cucumber and Its Potential Health Benefits: A Comprehensive Review. J. Agric. Food Chem. 2022, 70, 7607–7625.

• 29.

  Parameswari, R.P.; Lakshmi, T. Microalgae as a potential therapeutic drug candidate for neurodegenerative diseases. J. Biotechnol. 2022, 358, 128–139.

• 30.

  Ding, J.; Liang, R.; Yang, Y.; et al. Optimization of pea protein hydrolysate preparation and purification of antioxidant peptides based on an in silico analytical approach. Lwt 2020, 123, 109126.

• 31.

  Malta, S.M.; Batista, L.L.; Silva, H.C.G.; et al. Identification of bioactive peptides from a Brazilian kefir sample, and their anti-Alzheimer potential in Drosophila melanogaster. Sci. Rep. 2022, 12, 11065.

• 32.

  Hsieh, L.-S.; Hsu, Y.-C.; Chiang, W.-D. Neuroprotective peptides isolated from flavourzyme-pea protein hydrolysate protect human SH-SY5Y cells from Aβ1-42 induced apoptosis. J. Funct. Foods 2023, 108, 105755.

• 33.

  Lu, Z.; Yang, J.; Xu, X.; et al. Regulation mechanisms of sea cucumber peptides against scopolamine-induced memory disorder and novel memory-improving peptides identification. Eur. J. Pharmacol. 2024, 968, 176430.

• 34.

  Wang, S.M.; Chuu, J.J.; Lee, C.K.; et al. Exploring the therapeutic efficacy of Chlorella pyrenoidosa peptides in ameliorating Alzheimer’s disease. Heliyon 2023, 9, e15406.

• 35.

  Ahmed, H.A.; Ishrat, T.; Pillai, B.; et al. Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study. Behav. Brain Res. 2018, 346, 29–40.

• 36.

  Labandeira-Garcia, J.L.; Rodriguez-Perez, A.I.; Garrido-Gil, P.; et al. Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration. Front. Aging Neurosci. 2017, 9, 129.

• 37.

  Jackson, L.; Eldahshan, W.; Fagan, S.C.; et al. Within the Brain: The Renin Angiotensin System. Int. J. Mol. Sci. 2018, 19, 876.

• 38.

  Chen, S.D.; Wu, C.L.; Lin, T.K.; et al. Renin inhibitor aliskiren exerts neuroprotection against amyloid beta-peptide toxicity in rat cortical neurons. Neurochem. Int. 2012, 61, 369–377.

• 39.

  Dong, Y.F.; Kataoka, K.; Toyama, K.; et al. Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension 2011, 58, 635–642.

• 40.

  Shinohara, K.; Liu, X.; Morgan, D.A.; et al. Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension. Hypertension 2016, 68, 1385–1392.

• 41.

  Labandeira-Garcia, J.L.; Labandeira, C.M.; Guerra, M.J.; et al. The role of the brain renin-angiotensin system in Parkinson’s disease. Transl. Neurodegener. 2024, 13, 22.

• 42.

  Perez-Lloret, S.; Otero-Losada, M.; Toblli, J.E.; et al. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease. Expert. Opin. Investig. Drugs 2017, 26, 1163–1173.

• 43.

  Kunkle, B.W.; Grenier-Boley, B.; Sims, R.; et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 2019, 51, 414–430.

• 44.

  Jochemsen, H.M.; Teunissen, C.E.; Ashby, E.L.; et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease. Alzheimer’s Res. Ther. 2014, 6, 27.

• 45.

  Xie, J.; Chen, S.; Huan, P.; et al. A novel angiotensin I-converting enzyme inhibitory peptide from walnut (Juglans sigillata) protein hydrolysates and its evaluation in Ang II-induced HUVECs and hypertensive rats. Int. J. Biol. Macromol. 2024, 266, 131152.

• 46.

  Song, W.; Huang, H.; Shen, Y.; et al. Hazelnut-Derived Peptide YYLLVR Improves Endothelial Dysfunction in Hypertension by Activating ACE2. J. Agric. Food Chem. 2025, 73, 17024–17039.

• 47.

  Van Thiel, B.S.; Goes Martini, A.; Te Riet, L.; et al. Brain Renin-Angiotensin System: Does It Exist? Hypertension 2017, 69, 1136–1144.

• 48.

  Biancardi, V.C.; Son, S.J.; Ahmadi, S.; et al. Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension 2014, 63, 572–579.

• 49.

  Ren, L.; Lu, X.; Danser, A.H.J. Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies. Curr. Hypertens. Rep. 2019, 21, 28.

• 50.

  Gouveia, F.; Camins, A.; Ettcheto, M.; et al. Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer’s disease: Past, present and future. Ageing Res. Rev. 2022, 77, 101612.

• 51.

  Subudhi, B.B.; Sahu, P.K. Chapter 4—Targeting Renin–Angiotensin System: A Strategy for Drug Development Against Neurological Disorders. In Angiotensin; Pilowsky, P.M., Ed.; Academic Press: Cambridge, MA, USA, 2023; pp. 107–150.

• 52.

  Inaba, S.; Iwai, M.; Furuno, M.; et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 2009, 53, 356–362.

• 53.

  Iwai, M.; Liu, H.W.; Chen, R.; et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004, 110, 843–848.

• 54.

  Chelmis, F.; Sorotou, I.; Pakataridis, P.; et al. The Ameliorative Effects of AT2 Receptor Activation with the Hexapeptide Novokinin on Streptozotocin-induced Model of Alzheimer’s Disease in SHR. Proc. Bulg. Acad. Sci. 2024, 77, 1852–1860.

• 55.

  Cosarderelioglu, C.; Nidadavolu, L.S.; George, C.J.; et al. Brain Renin-Angiotensin System at the Intersect of Physical and Cognitive Frailty. Front. Neurosci. 2020, 14, 586314.

• 56.

  Labandeira-Garcia, J.L.; Rodriguez-Pallares, J.; Villar-Cheda, B.; et al. Aging, Angiotensin System and Dopaminergic Degeneration in the Substantia Nigra. Aging Dis. 2011, 2, 257–274.

• 57.

  Mei, M.; Zhou, Y.; Liu, M.; et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson’s disease. Neuropharmacology 2019, 160, 107758.

• 58.

  Delva, A.; Van Weehaeghe, D.; Koole, M.; et al. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson’s Disease. Mov. Disord. 2020, 35, 1977–1986.

• 59.

  Gildea, J.J. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr. Opin. Nephrol. Hypertens. 2009, 18, 28–32.

• 60.

  Buck, S.A.; Erickson-Oberg, M.Q.; Bhatte, S.H.; et al. Roles of VGLUT2 and Dopamine/Glutamate Co-Transmission in Selective Vulnerability to Dopamine Neurodegeneration. ACS Chem. Neurosci. 2022, 13, 187–193.

• 61.

  Daniels, R.W.; Miller, B.R.; DiAntonio, A. Increased vesicular glutamate transporter expression causes excitotoxic neurodegeneration. Neurobiol. Dis. 2011, 41, 415–420.

• 62.

  Gabor, A.; Leenen, F.H. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension. Hypertension 2013, 61, 1083–1090.

• 63.

  Kim, O.-H.; Lee, G.Y.; Kim, K.Y.; et al. 3-Hydroxymorphinan protects against hypoxia-induced cell death in primary astrocyte by regulating Ca2+ influx and the glutamate homeostasis. Mol. Cell. Toxicol. 2022, 19, 145–153.

• 64.

  Xu, J.; Sriramula, S.; Lazartigues, E. Excessive Glutamate Stimulation Impairs ACE2 Activity Through ADAM17-Mediated Shedding in Cultured Cortical Neurons. Cell Mol. Neurobiol. 2018, 38, 1235–1243.

• 65.

  Ceyzeriat, K.; Gloria, Y.; Tsartsalis, S.; et al. Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer’s disease. Brain Commun. 2021, 3, fcab029.

• 66.

  Klempin, F.; Mosienko, V.; Matthes, S.; et al. Depletion of angiotensin-converting enzyme 2 reduces brain serotonin and impairs the running-induced neurogenic response. Cell Mol. Life Sci. 2018, 75, 3625–3634.

• 67.

  Tian, J.; Stucky, C.S.; Wang, T.; et al. Mitochondrial Dysfunction Links to Impaired Hippocampal Serotonin Release in a Mouse Model of Alzheimer’s Disease. J. Alzheimers Dis. 2023, 93, 605–619.

• 68.

  Szapacs, M.E.; Mathews, T.A.; Tessarollo, L.; et al. Exploring the relationship between serotonin and brain-derived neurotrophic factor: Analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J. Neurosci. Methods 2004, 140, 81–92.

• 69.

  Duffuler, P.; Bhullar, K.S.; de Campos Zani, S.C.; et al. Bioactive Peptides: From Basic Research to Clinical Trials and Commercialization. J. Agric. Food Chem. 2022, 70, 3585–3595.

• 70.

  Basha, S.; Ks, P.; Chattopadhyay, A.; et al. Emerging insights into dairy products and Alzheimer’s disease: Exploring the potential neuroprotective effects. Crit. Rev. Food Sci. Nutr. 2025, 1–28. https://doi.org/10.1080/10408398.2025.2578711.

• 71.

  Akazawa, N.; Hamasaki, A.; Tanahashi, K.; et al. Lactotripeptide ingestion increases cerebral blood flow velocity in middle-aged and older adults. Nutr. Res. 2018, 53, 61–66.

• 72.

  Butikofer, U.; Meyer, J.; Sieber, R.; et al. Occurrence of the angiotensin-converting enzyme inhibiting tripeptides Val-Pro-Pro and Ile-Pro-Pro in different cheese varieties of Swiss origin. J. Dairy. Sci. 2008, 91, 29–38.

• 73.

  Aihara, K.; Kajimoto, O.; Hirata, H.; et al. Effect of Powdered Fermented Milk with Lactobacillus helveticus on Subjects with High-Normal Blood Pressure or Mild Hypertension. J. Am. Coll. Nutr. 2005, 24, 257–265.

• 74.

  Kajimoto, O.; Aihara, K.; Hirata, H.; et al. Hypotensive Effects of The Tablets Containing “Lactotripeptides (VPP, IPP)”. J. Nutr. Food 2001, 4, 51–61.

• 75.

  Gregory, K.S.; Cozier, G.E.; Schwager, S.L.U.; et al. Structural insights into the inhibitory mechanism of angiotensin-I-converting enzyme by the lactotripeptides IPP and VPP. FEBS Lett. 2024, 598, 242–251.

• 76.

  Yamada, A.; Sakurai, T.; Ochi, D.; et al. Novel angiotensin I-converting enzyme inhibitory peptide derived from bovine casein. Food Chem. 2013, 141, 3781–3789.

• 77.

  Tada, A.M.; Hamezah, H.S.; Yanagisawa, D.; et al. Neuroprotective Effects of Casein-Derived Peptide Met-Lys-Pro (MKP) in a Hypertensive Model. Front. Neurosci. 2020, 14, 845.

• 78.

  Sanjukta, S.; Rai, A.K. Production of bioactive peptides during soybean fermentation and their potential health benefits. Trends Food Sci. Technol. 2016, 50, 1–10.

• 79.

  Patel, K.; Mani, A. Food-derived Peptides as Promising Neuroprotective Agents: Mechanism and Therapeutic Potential. Curr. Top. Med. Chem. 2024, 24, 1212–1229.

• 80.

  Ju, D.T.; Kuo, W.W.; Ho, T.-J.; et al. Bioactive Peptide VHVV Upregulates the Long-Term Memory-Related Biomarkers in Adult Spontaneously Hypertensive Rats. Int. J. Mol. Sci. 2019, 20, 3069.

• 81.

  Song, W.; Fu, J.; Zeng, Q.; et al. Improving ACE inhibitory activity of hazelnut peptide modified by plastein: Physicochemical properties and action mechanism. Food Chem. 2023, 402, 134498.

• 82.

  Zhao, F.; Guo, L.; Huang, T.; et al. Interaction between the Neuroprotective and Hyperglycemia Mitigation Effects of Walnut-Derived Peptide LVRL via the Wnt3a/β-Catenin/GSK-3β Pathway in a Type 2 Diabetes Mellitus Model. J. Agric. Food Chem. 2024, 72, 16204–16220.

• 83.

  Zheng, X.; Li, D.S.; Ding, K. Purification and identification of angiotensin I-converting enzyme inhibitory peptides from fermented walnut residues. Int. J. Food Prop. 2018, 20, S3326–S3333.

• 84.

  Zhao, F.; Liu, C.; Fang, L.; et al. Walnut-Derived Peptide Activates PINK1 via the NRF2/KEAP1/HO-1 Pathway, Promotes Mitophagy, and Alleviates Learning and Memory Impairments in a Mice Model. J. Agric. Food Chem. 2021, 69, 2758–2772.

• 85.

  Li, X.; Guo, M.; Chi, J.; et al. Bioactive Peptides from Walnut Residue Protein. Molecules 2020, 25, 1285.

• 86.

  Li, Z.; Dang, Q.; Wang, P.; et al. Food-Derived Peptides: Beneficial CNS Effects and Cross-BBB Transmission Strategies. J. Agric. Food Chem. 2023, 71, 20453–20478.

• 87.

  Zheng, J.; Gao, Y.; Ding, J.; et al. Antarctic krill peptides improve scopolamine-induced memory impairment in mice. Food Biosci. 2022, 49, 101987.

• 88.

  Ren, Q.; Jiang, X.; Zhang, S.; et al. Neuroprotective effect of YIAEDAER peptide against Parkinson’s disease like pathology in zebrafish. Biomed. Pharmacother. 2022, 147, 112629.

• 89.

  Yang, J.; Ding, J.; Lu, Z.; et al. Digestive and Absorptive Properties of the Antarctic Krill Tripeptide Phe-Pro-Phe (FPF) and Its Auxiliary Memory-Enhancing Effect. J. Agric. Food Chem. 2024, 72, 8491–8505.

• 90.

  Zhang, Q.; Zhao, L.; Li, C.; et al. Investigation of a Neuroprotective Peptide from Round Scad (Decapterus maruadsi): Bioactivity Validation, Gastrointestinal Digestion Stability, and Structure-Activity Relationship Analysis. J. Agric. Food Chem. 2025, 73, 32302–32314.

• 91.

  Lu, Z.; Lv, R.; Dong, L.; et al. Sea cucumber peptides protect against memory impairment by regulating dopamine/serotonin metabolization and synapse plasticity of mice hippocampus. J. Funct. Foods 2023, 108, 105732.

• 92.

  Lemus-Conejo, A.; Millan-Linares, M.D.C.; Toscano, R.; et al. GPETAFLR, a peptide from Lupinus angustifolius L. prevents inflammation in microglial cells and confers neuroprotection in brain. Nutr. Neurosci. 2022, 25, 472–484.

• 93.

  Ni, L.; Zhuge, F.; Yang, S.; et al. Hydrolyzed Chicken Meat Extract Attenuates Neuroinflammation and Cognitive Impairment in Middle-Aged Mouse by Regulating M1/M2 Microglial Polarization. J. Agric. Food Chem. 2021, 69, 9800–9812.

• 94.

  Li, B.; Shi, X.; Chen, E.; et al. Improvement effects of cyclic peptides from Annona squamosa on cognitive decline in neuroinflammatory mice. Food Sci. Biotechnol. 2024, 33, 1437–1448.

• 95.

  Min, L.J.; Kobayashi, Y.; Mogi, M.; et al. Administration of bovine casein-derived peptide prevents cognitive decline in Alzheimer disease model mice. PLoS ONE 2017, 12, e0171515.

• 96.

  Rizzetti, D.A.; Fernandez, F.; Moreno, S.; et al. Egg white hydrolysate promotes neuroprotection for neuropathic disorders induced by chronic exposure to low concentrations of mercury. Brain Res. 2016, 1646, 482–489.

• 97.

  Yu, T.; Guo, J.; Zhu, S.; et al. Protective effects of selenium-enriched peptides from Cardamine violifolia on d-galactose-induced brain aging by alleviating oxidative stress, neuroinflammation, and neuron apoptosis. J. Funct. Foods 2020, 75, 104277.

• 98.

  Reed, B.N.; Sueta, C.A. A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). Curr. Cardiol. Rev. 2015, 11, 23–32.

• 99.

  Esteras, R.; Perez-Gomez, M.V.; Rodriguez-Osorio, L.; et al. Combination use of medicines from two classes of renin–angiotensin system blocking agents: Risk of hyperkalemia, hypotension, and impaired renal function. Ther. Adv. Drug Saf. 2015, 6, 166–176.

• 100.

  Schaafsma, G. Safety of protein hydrolysates, fractions thereof and bioactive peptides in human nutrition. Eur. J. Clin. Nutr. 2009, 63, 1161–1168.

• 101.

  Chakrabarti, S.; Jahandideh, F.; Wu, J. Food-derived bioactive peptides on inflammation and oxidative stress. Biomed. Res. Int. 2014, 2014, 608979.

• 102.

  Meleti, E.; Koureas, M.; Manouras, A.; et al. Bioactive Peptides from Dairy Products: A Systematic Review of Advances, Mechanisms, Benefits, and Functional Potential. Dairy 2025, 6, 65.

• 103.

  Chakrabarti, S.; Guha, S.; Majumder, K. Food-Derived Bioactive Peptides in Human Health: Challenges and Opportunities. Nutrients 2018, 10, 1738.

• 104.

  Jacob, M.C.M.; da Silva-Maia, J.K.; Albuquerque, U.P.; et al. Culture matters: A systematic review of antioxidant potential of tree legumes in the semiarid region of Brazil and local processing techniques as a driver of bioaccessibility. PLoS ONE 2022, 17, e0264950.

• 105.

  Zhang, Q.; Zheng, L.; Luo, D.; et al. In Vitro Simulated Gastrointestinal Digestion Stability of a Neuroprotective Octapeptide WCPFSRSF and Prediction of Potential Bioactive Peptides in Its Digestive Fragments by Multiple Bioinformatics Tools. J. Agric. Food Chem. 2023, 71, 6987–6998.

• 106.

  Pavlicevic, M.; Maestri, E.; Marmiroli, M. Marine Bioactive Peptides-An Overview of Generation, Structure and Application with a Focus on Food Sources. Mar. Drugs 2020, 18, 424.

• 107.

  Bhattacharjee, M.J.; Bala, A.; Khan, M.R.; et al. Functional impact of bioactive peptides derived from fermented foods on diverse human populations. Food Chem. 2025, 492, 145416.

• 108.

  Cicero, A.F.G.; Fogacci, F.; Colletti, A. Potential role of bioactive peptides in prevention and treatment of chronic diseases: A narrative review. Br. J. Pharmacol. 2017, 174, 1378–1394.

• 109.

  Majura, J.J.; Cao, W.; Chen, Z.; et al. The current research status and strategies employed to modify food-derived bioactive peptides. Front. Nutr. 2022, 9, 950823.

• 110.

  Vlieghe, P.; Khrestchatisky, M. Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system. Ther. Deliv. 2010, 1, 489–494.

• 111.

  Zhang, X.; Tu, D.; Li, S.; et al. A novel synthetic peptide SVHRSP attenuates dopaminergic neurodegeneration by inhibiting NADPH oxidase-mediated neuroinflammation in experimental models of Parkinson’s disease. Free Radic. Biol. Med. 2022, 188, 363–374.

• 112.

  Ano, Y.; Kutsukake, T.; Sasaki, T.; et al. Identification of a Novel Peptide from β-Casein That Enhances Spatial and Object Recognition Memory in Mice. J. Agric. Food Chem. 2019, 67, 8160–8167.

• 113.

  Shah, S.A.; Lee, H.Y.; Bressan, R.A.; et al. Novel osmotin attenuates glutamate-induced synaptic dysfunction and neurodegeneration via the JNK/PI3K/Akt pathway in postnatal rat brain. Cell Death Dis. 2014, 5, e1026.

• 114.

  Zhang, T.L.; Fu, J.L.; Geng, Z.; et al. The neuroprotective effect of losartan through inhibiting AT1/ASK1/MKK4/JNK3 pathway following cerebral I/R in rat hippocampal CA1 region. CNS Neurosci. Ther. 2012, 18, 981–987.

• 115.

  Gupta, N.; Quazi, S.; Jha, S.K.; et al. Chickpea Peptide: A Nutraceutical Molecule Corroborating Neurodegenerative and ACE-I Inhibition. Nutrients 2022, 14, 4824.

• 116.

  Roy, F.; Boye, J.I.; Simpson, B.K. Bioactive proteins and peptides in pulse crops: Pea, chickpea and lentil. Food Res. Int. 2010, 43, 432–442.

• 117.

  Mukhamedov, N.; Asrorov, A.; Yashinov, A.; et al. Synthesis and Characterisation of Chickpea Peptides-Zinc Chelates Having ACE2 Inhibitory Activity. Protein J. 2023, 42, 547–562.

• 118.

  Suwanangul, S.; Aluko, R.E.; Sangsawad, P.; et al. Antioxidant and enzyme inhibitory properties of sacha inchi (Plukenetia volubilis) protein hydrolysate and its peptide fractions. J. Food Biochem. 2022, 46, e14464.

• 119.

  Yang, P.; Abel-Hamid, M.; Romieh, E.; et al. Effect of peptides synthesized from lactoferrin of buffalo milk on oxidative stress in kunming mice. J. Anim. Plant Sci. 2020, 30, 65–71.

• 120.

  Martinez Leo, E.E.; Segura Campos, M.R. Neuroprotective effect from Salvia hispanica peptide fractions on pro-inflammatory modulation of HMC3 microglial cells. J. Food Biochem. 2020, 44, e13207.

• 121.

  Abdul-Muneer, P.M.; Bhowmick, S.; Briski, N. Angiotensin II Causes Neuronal Damage in Stretch-Injured Neurons: Protective Effects of Losartan, an Angiotensin T1 Receptor Blocker. Mol. Neurobiol. 2018, 55, 5901–5912.

• 122.

  Zhao, Y.T.; Yin, H.; Hu, C.; et al. Tilapia Skin Peptides Ameliorate Cyclophosphamide-Induced Anxiety- and Depression-Like Behavior via Improving Oxidative Stress, Neuroinflammation, Neuron Apoptosis, and Neurogenesis in Mice. Front. Nutr. 2022, 9, 882175.

• 123.

  Zhu, W.-Y.; Wang, Y.-M.; Dong, X.-M.; et al. Antioxidant peptides from Antarctic krill (Euphausia superba) hydrolysate: Stability, ACE inhibitory activity, and endothelial cells protection by regulating Keap1/Nrf2 pathway. J. Agric. Food Res. 2025, 20, 101745.

• 124.

  Dong, Y.; Hu, Q.; Zhao, L.; et al. A novel neuroprotective peptide YVYAETY identified and screened from Flammulina velutipes protein hydrolysates attenuates scopolamine-induced cognitive impairment in mice. Food Funct. 2024, 15, 6082–6094.

• 125.

  Wang, S.; Wu, S.; Yang, G.; et al. A review on the progress, challenges and prospects in commercializing microalgal fucoxanthin. Biotechnol. Adv. 2021, 53, 107865.

• 126.

  Bamdad, F.; Shin, S.H.; Suh, J.W.; et al. Anti-Inflammatory and Antioxidant Properties of Casein Hydrolysate Produced Using High Hydrostatic Pressure Combined with Proteolytic Enzymes. Molecules 2017, 22, 609.

• 127.

  Haqqani, A.S.; Belanger, K.; Stanimirovic, D.B. Receptor-mediated transcytosis for brain delivery of therapeutics: Receptor classes and criteria. Front. Drug Deliv. 2024, 4, 1360302.

• 128.

  Tang, J.; Krushelnycky, L.; Shaqo, A.; et al. A Comprehensive Review of Nutritional Influences on the Serotonergic System. Adv. Nutr. 2025, 16, 100524.

• 129.

  Liu, Z.; Udenigwe, C.C. Role of food-derived opioid peptides in the central nervous and gastrointestinal systems. J. Food Biochem. 2019, 43, e12629.

• 130.

  Sakaguchi, M.; Koseki, M.; Wakamatsu, M.; et al. Effects of systemic administration of β-casomorphin-5 on learning and memory in mice. Eur. J. Pharmacol. 2006, 530, 81–87.

• 131.

  Dang, Q.; Wu, D.; Li, Y.; et al. Walnut-derived peptides ameliorate d-galactose-induced memory impairments in a mouse model via inhibition of MMP-9-mediated blood-brain barrier disruption. Food Res. Int. 2022, 162, 112029.

• 132.

  Chataigner, M.; Mortessagne, P.; Lucas, C.; et al. Dietary fish hydrolysate supplementation containing n-3 LC-PUFAs and peptides prevents short-term memory and stress response deficits in aged mice. Brain Behav. Immun. 2021, 91, 716–730.

• 133.

  Diez-Vives, C.; Gay, M.; Garcia-Matas, S.; et al. Proteomic study of neuron and astrocyte cultures from senescence-accelerated mouse SAMP8 reveals degenerative changes. J. Neurochem. 2009, 111, 945–955.

• 134.

  Furukawa, A.; Oikawa, S.; Hasegawa-Ishii, S.; et al. Proteomic analysis of aging brain in SAMP10 mouse: A model of age-related cerebral degeneration. Mech. Ageing Dev. 2010, 131, 379–388.

• 135.

  Seino, Y.; Kawarabayashi, T.; Wakasaya, Y.; et al. Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model. J. Neurosci. Res. 2010, 88, 3547–3554.

• 136.

  Li, Y.; Qiang, X.; Luo, L.; et al. Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2017, 126, 762–775.

• 137.

  Lawlor, P.A.; Young, D. Aβ Infusion and Related Models of Alzheimer Dementia. In Animal Models of Dementia; Humana Press: Totowa, NJ, USA, 2011; pp. 347–370.

• 138.

  Liu, L.; Li, S.; Zheng, J.; et al. Safety considerations on food protein-derived bioactive peptides. Trends Food Sci. Technol. 2020, 96, 199–207.

• 139.

  Katayama, S.; Imai, R.; Sugiyama, H.; et al. Oral administration of soy peptides suppresses cognitive decline by induction of neurotrophic factors in SAMP8 mice. J. Agric. Food Chem. 2014, 62, 3563–3569.

• 140.

  Feng, L.; Wang, X.; Peng, F.; et al. Walnut Protein Hydrolysates Play a Protective Role on Neurotoxicity Induced by d-Galactose and Aluminum Chloride in Mice. Molecules 2018, 23, 2308.

• 141.

  Wu, D.; Li, M.; Ding, J.; et al. Structure-activity relationship and pathway of antioxidant shrimp peptides in a PC12 cell model. J. Funct. Foods 2020, 70, 103978.

• 142.

  Zhao, Y.; Lu, Z.; Xu, X.; et al. Sea Cucumber-Derived Peptide Attenuates Scopolamine-Induced Cognitive Impairment by Preventing Hippocampal Cholinergic Dysfunction and Neuronal Cell Death. J. Agric. Food Chem. 2022, 70, 567–576.

• 143.

  Ren, D.; Zhao, F.; Liu, C.; et al. Antioxidant hydrolyzed peptides from Manchurian walnut (Juglans mandshurica Maxim.) attenuate scopolamine-induced memory impairment in mice. J. Sci. Food Agric. 2018, 98, 5142–5152.

• 144.

  Zou, J.; Cai, P.S.; Xiong, C.M.; et al. Neuroprotective effect of peptides extracted from walnut (Juglans sigilata Dode) proteins on Aβ25-35-induced memory impairment in mice. J. Huazhong Univ. Sci. Technol. Med. Sci. 2016, 36, 21–30.